Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics' Nine-Month Revenues Drop Sharply

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today reported that its nine-month revenues declined 58 percent from the comparable period in 2009.

The Berlin, Germany-based molecular diagnostics developer reported total revenues of €1.3 million ($1.8 million) for the first nine months of 2010, a sharp drop from €3.2 million for the first nine months of 2009. The firm said that the 2009 period included non-recurring payments from R&D and licensing partnerships.

Epigenomics' net loss was €8.4 million compared to €7.1 million from the previous year.

"Our dual track commercial strategy is developing well with new partners and distributors on board giving us access to new markets and countries with our test and technology," Epigenomics CEO Geert Nygaard said in a statement.

The firm is selling its Epi proColon kits directly in Germany and Switzerland and inked a non-exclusive marketing deal for Canada with Warnex. It also has licensed rights to the Septin9 biomarker, on which the colorectal cancer test is based, to Quest Diagnostics and ARUP Laboratories in the US and to Abbott in the European Union and the Asia-Pacific region.

"Sales growth is taking longer than expected due to slower initial uptake of our test and this is likely going to continue at a gradual pace during 2011," said Nygaard. "However, we are taking proactive steps to reach out to the medical profession about the benefits of the test to patients."

Epigenomics said that it had liquid assets of €29.6 million as of Sept. 30.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.